NASDAQ$XWEL
XpresSpa Group Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Reported results for the third quarter of 2022, showing a shift in direction as a leading authority in wellness for ‘People on the Go’ after rebranding as XWELL.
XWELL, Inc. reported a total revenue of $10.7 million for the third quarter of 2022, compared to $26.8 million in the corresponding period in 2021. The company experienced a net loss attributable to common shareholders of $7.2 million, compared to a net income of $5.6 million in the prior year third quarter. Despite the losses, the company is focused on strategic objectives, international expansion, retail strategy implementation, and cost reduction to achieve profitability in 2023.
- Total revenue for Q3 2022 was $10.7 million, a decrease from $26.8 million in Q3 2021.
- Net loss attributable to common shareholders was $7.2 million in Q3 2022, compared to net income of $5.6 million in Q3 2021.
- The company closed five unprofitable XpresCheck locations during the third quarter and plans to close another seven in the fourth quarter.
- XWELL's partnership with Ginkgo Bioworks secured a new contract worth approximately $16 million, with a potential to reach $61 million based on CDC program options.
Headline financials
Revenue & EPS history
XpresSpa · Revenue · Quarterly
$10.7M
Revenue by segment
XpresSpa · $6.64M total across 3 segments · Q1 2026
- XpresSpa$4.2M—63.2%
- XpresTest$1.92M—28.9%
- Naples Wax$524K—7.9%
Forward guidance
The Company believes it is entering 2023 as a leaner business with a path to returned profitability and is well positioned to achieve its growth goals.
Tailwinds
- Expanding internationally with new XpresSpa locations in Istanbul.
- Implementing a new retail strategy to drive more foot traffic into airport locations.
- Adding new technologies and trends, including tech-forward equipment.
- Offering diagnostic testing, hydration therapy, IV drips, and vitamin injections at Treat locations.
- Continuing biosurveillance partnership with Ginkgo Bioworks and the CDC.
Headwinds
- Decreased testing volumes at XpresCheck locations due to relaxed testing requirements.
- Closing unprofitable XpresCheck locations to optimize performance.
- Q3 2022 total revenue decreased compared to Q3 2021.
- Q3 2022 net loss attributable to common shareholders, compared to net income in Q3 2021.
- Adjusted EBITDA was negative during the third quarter 2022, compared to positive Adjusted EBITDA in the prior year third quarter.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2022
+1.1%
Avg return
Earnings day
-2.3%
Avg return
5 days after
-4.5%
Avg return
30 days after
43%
16 / 37 earnings
Positive
+24.4%
Q4 2019
Best reaction
-11.1%
Q4 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | — | — | — | |
| Q3 2025 | +0.0% | -8.4% | -9.6% | |
| Q2 2025 | -5.8% | -8.3% | -8.3% | |
| Q1 2025 | +1.2% | +12.8% | +9.3% | |
| Q4 2024 | +0.0% | +0.0% | +15.4% | |
| Q3 2024 | -1.2% | -10.6% | -24.1% | |
| Q2 2024 | +3.7% | +0.5% | -14.8% | |
| Q1 2024 | +3.4% | -8.4% | +41.6% | |
| Q4 2023 | +0.0% | +0.7% | +32.1% | |
| Q3 2023 | +6.2% | +35.4% | +31.1% | |
| Q2 2023 | -4.2% | -4.2% | -25.0% | |
| Q1 2023 | +0.0% | +4.2% | +4.2% | |
| Q4 2022 | +6.3% | -9.4% | -21.9% | |
| Q3 2022 | +0.0% | -12.3% | -10.5% | |
| Q2 2022 | -6.5% | -5.4% | +9.7% | |
| Q1 2022 | -1.1% | -18.7% | -22.0% | |
| Q4 2021 | +8.2% | +52.0% | +11.2% | |
| Q3 2021 | +11.7% | +13.1% | +25.5% | |
| Q2 2021 | -6.9% | -13.1% | -2.9% | |
| Q4 2020 | +6.4% | -3.5% | -20.8% | |
| Q3 2020 | -1.1% | -13.4% | -22.5% | |
| Q2 2020 | -6.5% | -4.2% | -42.9% | |
| Q1 2020 | -7.5% | -5.5% | +6.5% | |
| Q4 2019 | +24.4% | +26.8% | +17.1% | |
| Q3 2019 | +2.0% | -5.9% | -41.6% | |
| Q2 2019 | +0.0% | +21.2% | +31.9% | |
| Q1 2019 | +7.8% | -9.0% | -40.0% | |
| Q4 2018 | +0.3% | -12.0% | -22.7% | |
| Q3 2018 | +0.0% | +0.0% | +11.1% | |
| Q2 2018 | +0.0% | -25.0% | -20.0% | |
| Q1 2018 | -4.8% | -31.7% | -20.6% | |
| Q4 2017 | -11.1% | -24.7% | -17.3% | |
| Q3 2017 | -0.8% | -4.0% | -6.5% | |
| Q2 2017 | +11.5% | +4.4% | +9.7% | |
| Q1 2017 | +4.9% | +1.9% | +5.6% | |
| Q4 2016 | +0.9% | -9.7% | -20.8% | |
| Q3 2016 | +0.8% | -8.0% | -15.6% | |
| Q2 2016 | -1.9% | -1.0% | +1.9% | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro